Candel Therapeutics reports Q2 2025 results

Candel Therapeutics, Inc. furnished an update on its business by announcing financial results for the quarter ended June 30, 2025.

Accepted by SEC EDGAR 08/14/2025 - 08:07 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Candel Therapeutics, Inc. furnished an update on its business by announcing financial results for the quarter ended June 30, 2025. The company reported these quarterly results through a press release dated August 14, 2025, which is attached as Exhibit 99.1 to this Form 8-K.

The information about these results, including the press release, is being furnished rather than filed, meaning it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other securities law filings unless specifically referenced. The report is signed on behalf of Candel Therapeutics by President and Chief Executive Officer Paul Peter Tak, M.D., Ph.D., FMedSci.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Candel Therapeutics (CADL) disclose in this Form 8-K?

Candel Therapeutics, Inc. disclosed that it announced its financial results for the quarter ended June 30, 2025, with details provided in a press release furnished as Exhibit 99.1.

Which period do the Candel Therapeutics (CADL) results in this filing cover?

The financial results referenced in this filing cover the quarter ended June 30, 2025.

How are the Candel Therapeutics (CADL) Q2 2025 results provided to investors?

The results are provided through a press release dated August 14, 2025, which is furnished as Exhibit 99.1 to this Form 8-K.

Is the Candel Therapeutics (CADL) earnings press release treated as filed with the SEC?

No. The information in this Form 8-K, including Exhibit 99.1, is furnished and is not deemed filed for purposes of Section 18 of the Exchange Act.

Can the Candel Therapeutics (CADL) press release be incorporated into other SEC filings?

It will not be incorporated into other Securities Act or Exchange Act filings except where Candel Therapeutics expressly incorporates it by specific reference in such a filing.

Who signed this Candel Therapeutics (CADL) Form 8-K?

The Form 8-K was signed on behalf of Candel Therapeutics, Inc. by Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false000184138700018413872025-08-142025-08-14

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2025

CANDEL THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-40629	52-2214851
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
117 Kendrick St Suite 450
Needham, Massachusetts				02494
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 916-5445

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value per share		CADL		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 14, 2025, Candel Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is furnished herewith and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press Release dated August 14, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Candel Therapeutics, Inc.
Date:	August 14, 2025	By:	/s/ Paul Peter Tak
			Paul Peter Tak, M.D., Ph.D., FMedSci President and Chief Executive Officer